GT Biopharma, Inc.
GTBP· Nasdaq
Filed Aug 14, 2025 · 10-Q · 45 days after period end · 0001493152-25-011971
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Net Income | -$30.17M | -$3.71M | -$1.99M | -$2.98M |
| EPS Diluted | -$10.92 | -$2.17 | -$1.49 | -$0.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
ended Jun 30, 2025 · filed Aug 14, 2025 · 45 d after period end